The Council of European BioRegions asbl (CEBR) is proud to announce Teijin Pharma Ltd as a sponsor of the CEBR SME Medical Device Directory and Hotlist in 2016.
As a network of 40 life science clusters across Europe, CEBR is dedicated to supporting cluster and SME development and has developed an online directory with its members, which showcases SMEs directly involved in the development of innovative medical devices. The directory, launched in 2016, creates a dynamic critical mass of novel technologies from Europe’s SMEs, enabling partners and investors across the world to find the right companies for development.
In spring 2016, CEBR also launched a ‘hotlist’ process, where cluster managers can nominate the medical device SME from within their community that has made the greatest progress since directory launch in June 2016. March 18 will see the publication of the hotlist, followed by an open webinar on April 11th at 1100 CET, where hotlist SMEs will present their company, technology and progress.
The support of Teijin Pharma Ltd reflects the value of cluster manager-driven SME support in finding the right SME partners across a complex European landscape and allows CEBR to expand its activities in providing global support to its members in growing their clusters. CEBR President, Frédéric Druck of Biowin, commented “We are delighted that the hard work of clusters in building and continuing to grow the Medical Device Directory is recognised by companies such as Teijin Pharma, as a tool in strengthening medical device development. SMEs work incredibly hard to build their products. Efforts from cluster managers and CEBR and support from Teijin can help them to achieve their goals.”
Taiichi Machida, of Teijin Pharma Ltd added “”We are honoured to be a sponsor of CEBR Medical Device Directory. The Directory is expected to bring win-win prosperity between SMEs and companies like us. To achieve this goal, we would contribute our humble efforts. Access to innovative small companies allows Teijin Pharma to stay at the forefront of technologies that benefit patients in Europe and Japan”
Building medical device collaborations
Teijin Pharma is the only company in Japan to operate both a home healthcare business and a pharmaceutical business. Our venture into home healthcare began in the 1970s, when Teijin researchers began working on developing oxygen concentrators in response to demand for oxygen units that incorporated an oxygen enriching membrane. The project was a succession of challenges, not only in terms of product development but also due to the need to establish a service network. The success of project members not only laid the foundation for home healthcare in Japan, but today, Teijin Pharma’s Home Oxygen Therapy (HOT) is considered a benchmark in the domestic market, establishing Teijin Pharma as a leader in the home healthcare industry in Japan.
Now we are looking for new medical devices for home-use. We make a search for start-ups and venture companies in Europe, US and Israel for joint collaboration and development of early-stage products that have the potential to be sold in Japan. We also seek late-stage products to sell exclusively in Japan. Our focused fields are Respiratory including Sleep disorders, Orthopedic, Cardiovascular and Neuroscience including Rehabilitation after Stroke.